Esophageal Carcinoma Incidence and Survival Analysis: A Population-Based Cancer Registry Study in Central India.
- 1Pathology, All India Institute of Medical Sciences, Nagpur, Nagpur, IND.
- 2Pathology, Mahatma Gandhi Institute of Medical Sciences, Wardha, IND.
- 3Pathology, All India Institute of Medical Sciences, Deoghar, Deoghar, IND.
Abstract
Introduction
This study aimed to estimate the incidence, mortality, and overall survival (OS) of esophageal cancer (EC) and to evaluate the association of clinicopathological characteristics and treatment modality with OS.Methods
A retrospective observational cohort study was conducted using data from the Population-Based Cancer Registry (PBCR) in rural central India. The dataset included 545 incident EC cases registered between 2010 and 2019, of which 476 were eligible for OS analysis. Incidence and mortality rates were estimated, OS was analyzed using the Kaplan-Meier method, and Cox proportional hazards regression was used to identify prognostic factors. Prespecified sensitivity analyses, including metastasis-adjusted and age-stratified Cox regression models, were performed to assess the robustness of the primary multivariable findings.Results
The age-standardized incidence rate (ASIR) of overall EC cases was 3.99 per 100,000 population (95% CI: 3.50-4.47), while the age-standardized mortality rate (ASMR) was 3.29 per 100,000 population (95% CI: 2.94-3.64). The overall median survival was 178.33 days (95% CI: 115.49-234.48). The OS rates at 1, 3, 5, and 10 years were 31.3%, 19.7%, 17.4%, and 14.6%, respectively. OS differed significantly according to tumor site (χ² = 5.24, p = 0.043), treatment modality (χ² = 15.42, p = 0.031), and metastatic status (χ² = 162.64, p < 0.001) on Kaplan-Meier analysis. Median survival was 232 days (95% CI: 159.59-304.41) for localized disease, 199 days (95% CI: 166.38-231.61) for regional disease, 68 days (95% CI: 54.21-81.79) for distant disease, and 28 days (95% CI: 15.56-40.44) for advanced disease. On univariable Cox regression, patients with middle-third tumors had a lower hazard of death than those with upper-third tumors (HR: 0.74, 95% CI: 0.56-0.98; p = 0.036), and this remained significant after adjustment for metastatic status and in the age-stratified sensitivity model, while metastatic disease was associated with progressively higher mortality. Radiotherapy plus chemotherapy and surgery plus chemotherapy were independently associated with lower mortality after multivariable adjustment (HR: 0.48, 95% CI: 0.28-0.85, p = 0.011; HR: 0.45, 95% CI: 0.21-0.94, p = 0.035, respectively). Age, sex, and histological type were not significantly associated with OS.Conclusion
EC demonstrated a substantial mortality burden and poor OS in this population-based cohort. Metastatic status was the strongest associated prognostic factor, while tumor site and treatment modality were associated with survival on Kaplan-Meier analysis. Radiotherapy plus chemotherapy and surgery plus chemotherapy remained independently associated with lower mortality after multivariable adjustment. These findings highlight the importance of early diagnosis, accurate assessment of disease extent, and appropriate multimodal management of EC.
Related
- Regional disparities in lung cancer surgery and survival in South Korea: a nationwide population-based retrospective cohort study using linked cancer registry and national health insurance data
- Sex- and Region-Specific Incidence and Mortality Trends in Laryngeal and Oropharyngeal Cancer: A 95,000-Case Population-Based Registry Analysis from Poland, 1999–2023
- EDRIC-associated immune injury correlates with one-third of the survival detriment of elective nodal irradiation in esophageal squamous cell carcinoma
- Survival and treatment selection in NUT carcinoma: a population-based study and propensity score-matched comparison with poorly differentiated head and neck squamous cell carcinoma
- Epidemiology, exposure patterns and survival of malignant mesothelioma in Apulia, Italy (1993–2025): a population-based retrospective registry study
BibTeX
@article{ghongade2026esophageal,
title = {{Esophageal Carcinoma Incidence and Survival Analysis: A Population-Based Cancer Registry Study in Central India.}},
author = {Pravinkumar V Ghongade and Bharat U Patil and Anupama Gupta and Swapna Maliye and Nitin Gangane},
journal = {Cureus},
year = {2026},
month = sep,
doi = {10.7759/cureus.116626},
url = {https://europepmc.org/article/MED/42909884},
note = {CC BY},
}
RIS
TY - JOUR
TI - Esophageal Carcinoma Incidence and Survival Analysis: A Population-Based Cancer Registry Study in Central India.
AU - Pravinkumar V Ghongade
AU - Bharat U Patil
AU - Anupama Gupta
AU - Swapna Maliye
AU - Nitin Gangane
PY - 2026
DA - 2026/09/21
JO - Cureus
DO - 10.7759/cureus.116626
UR - https://europepmc.org/article/MED/42909884
AB - Introduction This study aimed to estimate the incidence, mortality, and overall survival (OS) of esophageal cancer (EC) and to evaluate the association of clinicopathological characteristics and treatment modality with OS.Methods A retrospective observational cohort study was conducted using data from the Population-Based Cancer Registry (PBCR) in rural central India. The dataset included 545 incident EC cases registered between 2010 and 2019, of which 476 were eligible for OS analysis. Incidence and mortality rates were estimated, OS was analyzed using the Kaplan-Meier method, and Cox proportional hazards regression was used to identify prognostic factors. Prespecified sensitivity analyses, including metastasis-adjusted and age-stratified Cox regression models, were performed to assess the robustness of the primary multivariable findings.Results The age-standardized incidence rate (ASIR) of overall EC cases was 3.99 per 100,000 population (95% CI: 3.50-4.47), while the age-standardized mortality rate (ASMR) was 3.29 per 100,000 population (95% CI: 2.94-3.64). The overall median survival was 178.33 days (95% CI: 115.49-234.48). The OS rates at 1, 3, 5, and 10 years were 31.3%, 19.7%, 17.4%, and 14.6%, respectively. OS differed significantly according to tumor site (χ² = 5.24, p = 0.043), treatment modality (χ² = 15.42, p = 0.031), and metastatic status (χ² = 162.64, p < 0.001) on Kaplan-Meier analysis. Median survival was 232 days (95% CI: 159.59-304.41) for localized disease, 199 days (95% CI: 166.38-231.61) for regional disease, 68 days (95% CI: 54.21-81.79) for distant disease, and 28 days (95% CI: 15.56-40.44) for advanced disease. On univariable Cox regression, patients with middle-third tumors had a lower hazard of death than those with upper-third tumors (HR: 0.74, 95% CI: 0.56-0.98; p = 0.036), and this remained significant after adjustment for metastatic status and in the age-stratified sensitivity model, while metastatic disease was associated with progressively higher mortality. Radiotherapy plus chemotherapy and surgery plus chemotherapy were independently associated with lower mortality after multivariable adjustment (HR: 0.48, 95% CI: 0.28-0.85, p = 0.011; HR: 0.45, 95% CI: 0.21-0.94, p = 0.035, respectively). Age, sex, and histological type were not significantly associated with OS.Conclusion EC demonstrated a substantial mortality burden and poor OS in this population-based cohort. Metastatic status was the strongest associated prognostic factor, while tumor site and treatment modality were associated with survival on Kaplan-Meier analysis. Radiotherapy plus chemotherapy and surgery plus chemotherapy remained independently associated with lower mortality after multivariable adjustment. These findings highlight the importance of early diagnosis, accurate assessment of disease extent, and appropriate multimodal management of EC.
SN - 2168-8184
ER -